111 related articles for article (PubMed ID: 32161011)
1. EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation
Agrawal R; Chen M; Bukhari Z; Ogunwobi OO; Haseeb MA; Martello LA
Ann Clin Lab Sci; 2020 Jan; 50(1):45-56. PubMed ID: 32161011
[TBL] [Abstract][Full Text] [Related]
2. Laser capture microdissection of pancreatic ductal adeno-carcinoma cells to analyze EzH2 by Western Blot analysis.
Qazi AM; Aggarwal S; Steffer CS; Bouwman DL; Weaver DW; Gruber SA; Batchu RB
Methods Mol Biol; 2011; 755():245-56. PubMed ID: 21761309
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells.
Naimi A; Safaei S; Entezari A; Solali S; Hassanzadeh A
Anticancer Agents Med Chem; 2020; 20(5):571-579. PubMed ID: 32000648
[TBL] [Abstract][Full Text] [Related]
5. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
6. EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma.
Batchu RB; Qazi AM; Gruzdyn OV; Semaan A; Seward SM; Chamala S; Dhulipala VB; Bouwman DL; Weaver DW; Gruber SA
Surgery; 2013 Oct; 154(4):739-46; discussion 746-7. PubMed ID: 24074410
[TBL] [Abstract][Full Text] [Related]
7. [MiR-150-5p inhibits the proliferation and promoted apoptosis of pancreatic cancer cells].
Sun Y; Jin XL; Zhang TT; Jia CW; Chen J
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):460-4. PubMed ID: 24246865
[TBL] [Abstract][Full Text] [Related]
8. Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells.
Guo W; Chen Y; Gao J; Zhong K; Wei H; Li K; Tang M; Zhao X; Liu X; Nie C; Yuan Z
Cell Cycle; 2019 Aug; 18(15):1745-1758. PubMed ID: 31213123
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer.
Lian Y; Wang J; Feng J; Ding J; Ma Z; Li J; Peng P; De W; Wang K
Tumour Biol; 2016 Nov; 37(11):14929-14937. PubMed ID: 27644252
[TBL] [Abstract][Full Text] [Related]
10. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Ougolkov AV; Bilim VN; Billadeau DD
Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological significance of
Roh JW; Choi JE; Han HD; Hu W; Matsuo K; Nishimura M; Lee JS; Kwon SY; Cho CH; Kim J; Coleman RL; Lopez-Bernstein G; Sood AK
Cancer Biol Ther; 2020; 21(2):147-156. PubMed ID: 31640461
[TBL] [Abstract][Full Text] [Related]
14. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.
Han T; Jiao F; Hu H; Yuan C; Wang L; Jin ZL; Song WF; Wang LW
Oncotarget; 2016 Mar; 7(10):11194-207. PubMed ID: 26848980
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
16. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
Cheng T; Xu Y
Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
18. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
19. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382.
Zhao L; Sun H; Kong H; Chen Z; Chen B; Zhou M
Cell Physiol Biochem; 2017; 42(6):2145-2158. PubMed ID: 28813705
[TBL] [Abstract][Full Text] [Related]
20. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
